ID   SNU-368
AC   CVCL_3948
SY   SNU368
DR   BTO; BTO:0003169
DR   Cosmic; 2023866
DR   GEO; GSM1374889
DR   GEO; GSM2551585
DR   IARC_TP53; 6305
DR   KCLB; 00368
DR   LIMORE; SNU368
DR   Wikidata; Q54955179
RX   PubMed=7543080;
RX   PubMed=8824565;
RX   PubMed=16616112;
RX   PubMed=19956504;
RX   PubMed=31063779;
RX   PubMed=31378681;
WW   https://lccl.zucmanlab.com/hcc/cellLines/SNU368
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Doubling time: 41 hours (PubMed=7543080); 42.77 hours (PubMed=31378681).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Leu1607Profs*41 (c.4817dupT); Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Gln184Ter (c.550C>T); Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser106Arg (c.318C>G); ClinVar=VCV000492752; Zygosity=Unspecified (PubMed=8824565; PubMed=31378681).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Liver.
ST   Source(s): KCLB; PubMed=31378681
ST   Amelogenin: X,Y
ST   CSF1PO: 10,13
ST   D13S317: 8,9
ST   D16S539: 12
ST   D3S1358: 16
ST   D5S818: 10
ST   D7S820: 11,12
ST   FGA: 25
ST   TH01: 6,9
ST   TPOX: 9,11
ST   vWA: 14,17
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 19
//
RX   PubMed=7543080; DOI=10.1002/ijc.2910620308;
RA   Park J.-G., Lee J.-H., Kang M.-S., Park K.-J., Jeon Y.-M., Lee H.-J.,
RA   Kwon H.-S., Park H.-S., Yeo K.-S., Lee K.-U., Kim S.-T., Chung J.-K.,
RA   Hwang Y.-J., Lee H.-S., Kim C.Y., Lee Y.I., Chen T.-R., Hay R.J.,
RA   Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.;
RT   "Characterization of cell lines established from human hepatocellular
RT   carcinoma.";
RL   Int. J. Cancer 62:276-282(1995).
//
RX   PubMed=8824565; DOI=10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X;
RA   Kang M.-S., Lee H.-J., Lee J.-H., Ku J.-L., Lee K.P., Kelley M.J.,
RA   Won Y.-J., Kim S.-T., Park J.-G.;
RT   "Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX
RT   DNA.";
RL   Int. J. Cancer 67:898-902(1996).
//
RX   PubMed=16616112; DOI=10.1016/j.cancergencyto.2005.08.022;
RA   Park S.-J., Jeong S.-Y., Kim H.J.;
RT   "Y chromosome loss and other genomic alterations in hepatocellular
RT   carcinoma cell lines analyzed by CGH and CGH array.";
RL   Cancer Genet. Cytogenet. 166:56-64(2006).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//